which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

The FDA approved the drug based off a late-stage clinical ... “It’s very important to recognize those early symptoms of Alzheimer’s and to get diagnosed early so these treatments are an ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

The designation is granted for its use in Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration. The FDA's Fast Track program expedites the development and review of drugs ...

The designation is granted for its use in Alzheimer’s disease ... degeneration. The FDA's Fast Track program expedites the development and review of drugs that treat serious conditions and ...

Digital twins are giving a shot in the arm to the costly, failure-prone drug-making process. But enormous data needs and ...

which is associated with Alzheimer's, from the brain," helping to slow cognitive decline. Another drug, donanemab, was approved by the FDA in July. The center has also seen drugs for other ...

AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration ... conditions: Alzheimer's disease, progressive supranuclear palsy ...

Yet living with uncontrolled hypertension may dramatically raise the risk of Alzheimer’s disease for people ages ... which means sitting on a hard-backed chair at a desk or table, not a sofa.

The $350 million Gladstone NOW campaign will raise funds to expand Gladstone's footprint, hire hundreds of additional ...